Biomm S.A. (BVMF:BIOM3)

Brazil flag Brazil · Delayed Price · Currency is BRL
7.04
+0.04 (0.57%)
Jun 27, 2025, 4:45 PM GMT-3
-49.71%
Market Cap 887.89M
Revenue (ttm) 143.94M
Net Income (ttm) -71.89M
Shares Out 126.84M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,000
Average Volume 84,947
Open 7.01
Previous Close 7.00
Day's Range 6.99 - 7.04
52-Week Range 6.52 - 16.00
Beta 0.72
RSI 27.29
Earnings Date Aug 14, 2025

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 130
Stock Exchange Brazil Stock Exchange
Ticker Symbol BIOM3
Full Company Profile

Financial Performance

In 2024, Biomm's revenue was 142.91 million, an increase of 20.91% compared to the previous year's 118.19 million. Losses were -77.24 million, -4.81% less than in 2023.

Financial Statements

News

There is no news available yet.